Join
Live feed
·
PRReleasevia Quantisnow
CorMedix Inc. logo

CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients

ByQuantisnow·Wall Street's wire, on your screen.
CRMD· CorMedix Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CRMD (CorMedix Inc.) and more on Quantisnow.